Pharmacogenetic monitoring of imantinib use in patientes with Chronic Myeloid Leukemia
DOI:
https://doi.org/10.5281/zenodo.8341213Keywords:
Chronic myeloid leukemia. Imantinib. PharmacogeneticsAbstract
Chronic Myeloid Leukemia (CML) is a malignant myeloproliferative neoplasm that accounts for 20% of all leukemias. In 90-95% of cases, this neoplasm is associated with the presence of the Philadelphia chromosome. Imatinib has been confirmed as a first-line therapy for the pharmacological treatment of CML because it has long-lasting responses in most patients, especially those in the chronic phase of the disease; however, some patients still in the chronic phase and a greater proportion in more advanced phases of CML present resistance or intolerance to imatinib, due to the therapeutic dose and the appearance of toxic effects. Another finding is related to the pharmacogenetic profile of the patients, which makes the treatment personalized. The general objective of this article is to carry out an integrative literature review regarding the pharmacogenetic monitoring of imatinib in patients with Chronic Myeloid Leukemia. Thirteen articles were found in the online databases, which met the inclusion and exclusion criteria of the research. It is concluded that the study of the pharmacogenetics of imatinib has been the subject of many recent studies. Therefore, its understanding can help to personalize the pharmacological treatment of the same and to improve the effectiveness of the drug in patients with CML and to minimize the appearance of adverse reactions and failures in the drug therapy.
Downloads
References
ALI, M.A. “Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.” Molecular diagnosis & therapy vol. 20,4: 315-33, 2016.
ANCESCHI, N.; DA SILVA GUERRA, L.D. A alocação de recursos para o tratamento medicamentoso oncológico no Sistema Único de Saúde– SUS. JMPHC, v. 12, n. spec: 1-2, 2020.
AZDEVEDO, L.D.; BASTOS, M.M.; OLIVEIRA, A.P.; BOECHATA, B. Sínteses e propriedades de fármacos inibidores da tirosina quinase BCR-ABL, utilizados no tratamento da leucemia mieloide crônica. Química Nova, v. 40: 791-809, 2017.
BOTELHO, L.L.R.; CUNHA, C.C.; MACEDO, M.O. O método da revisão integrativa nos estudos organizacionais. Gestão e Sociedade, v. 5, n. 11:121- 136, 2011.
CALDATO, T. Terapia celular no tratamento da leucemia mieloide crônica. Revista Saúde UniToledo, v. 3. n. 2: 50-61, 2019.
FACCIOLLI, P.B. “Adesão ao tratamento dos pacientes com leucemia mielóide crônica em uso de imatinibe." Monografia apresentada ao Programa de Aprimoramento Profissional /CRH/SES-SP. (2013): 52-52.
LIMA, A.G.; COELHO, J.L.G.; PEREIRA, M.J.A.; SARAIVA, S.E.M.; FEITOSA, R.A.; SANTANA, W.J. A Prática da Farmácia Clínica em Oncologia . Id on Line Rev.Mult. Psic. vol.15, n.54, p. 853-860, 2021.
MIRSAFIAN, H.; RAZMKHAH, F.; DORGALALEH, A.; AZIZI, E. Association of MTHFR C677T and A1298C gene polymorphisms with imatinib response and clinical outcomes in chronic myeloid leukemia. 2020, p. 3365.
OLIVEIRA, I.; MANDEL, M.; HOLTZ, L.; SANTOS, A.; BARBOSA, M.V.; CARLONI, M. CLARK, O.A. O impacto da pandemia da COVID-19 nos exames de rastreamento do câncer no Brasil: um estudo comparativo dos cânceres de mama, próstata e colo de útero. J. bras. econ. Saúde. 14, (3), 2022.
OLIVEIRA, A.; MUNHOZ, E.C.; MUNHOZ, J.M.N.; CARNEIRO, M.B. Avaliação da adesão ao mesilato de imatinibe de pacientes com Leucemia Mielóide Crônica. Rev. Bras. Farm. Hosp. Serv. Saúde São Paulo. v.4 n.3: 6-12, 2013.
RAVEGNINI, G.; SAMMARINI, G.; ANGELINI, S.; HRELIA, P. Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia. Expert Opin Drug Metab Toxicol. Jul;12 (7):733-42, 2016.
RIBEIRO, A.C.A.; PRATTI, J.E.S.; NOGUEIRA, T.A.; CORDEIRO, B.C. Acompanhamento Farmacoterpêutico e a Detecção de Reações Adversas a Inibidores de Tirosinoquinase utilizados no Tratamento da Leucemia Mielóide Crônica / Pharmacotherapeutic Follow-up and Detection of Adverse Reactions to Tyrosinokinase Inhibitors used in the Treatment of Chronic Myeloid Leukemia. Brazilian Journal of Health Review. 3, (6), 194, 2020.
SANTOS, M.M.F.; JESUS, G.P.; FERREIRA, L.P.; FRANÇA, R.F. Leucemia mielóide, aguda e crônica: diagnósticos e possíveis tratamentos. Revista Saúde em foco. n 11: 279-294, 2019.
SCHIFFER, C.A.; CORTES, J.E.; HOCHHAUS, A.; SAGLIO, G.; LE COUTRE, P.D.; BACCARANI, M. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: effects on response and toxicity. 2016: p. 1398.
SILVA, A.V.B.A.; NETO, E.M.R.; JUNIOR, FJ.F.; ARAÚJO, P.M.C.; VIANA, E.DR.N.; FONTELES, M.M.F. Acompanhamento farmacoterapêutico em leucemia mieloide crônica: avaliação das intervenções farmacêuticas. Boletim Informativo Geum. v. 7, n. 1, p. 82-92, 2016.
ZHOU, J.; XIE, L.; HE, S.; CHEN W ZHANG, Y.; WU X, Y.X. Association of CYP1A1 gene polymorphisms with imatinib pharmacokinetics in patients with gastrointestinal stromal tumors. 2013, p. 1084.
